Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Bradley J. Monk, MD, FACS, FACOG, discusses the clinical implications of the phase 3 PRIMA trial in newly diagnosed advanced ovarian cancer.